🇺🇸 potassium losartan in United States

128 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 128

Most-reported reactions

1. Fatigue — 22 reports (17.19%)
2. Nausea — 16 reports (12.5%)
3. Diarrhoea — 14 reports (10.94%)
4. Headache — 13 reports (10.16%)
5. Asthenia — 11 reports (8.59%)
6. Dizziness — 11 reports (8.59%)
7. Pneumonia — 11 reports (8.59%)
8. Anaemia — 10 reports (7.81%)
9. Drug Ineffective — 10 reports (7.81%)
10. Pyrexia — 10 reports (7.81%)

Source database →

Frequently asked questions

Is potassium losartan approved in United States?

potassium losartan does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for potassium losartan in United States?

Fifth Affiliated Hospital, Sun Yat-Sen University is the originator. The local marketing authorisation holder may differ — check the official source linked above.